NEXT:
Next Page Goes Here

LINZESS® (linaclotide) Instant Savings Program

FOR YOUR PATIENTS

LINZESS Savings Program LINZESS Savings Program Rules

COMMERCIALLY INSURED PATIENTS

For most commercially insured patients, the savings will be applied automatically at the pharmacy; no coupon is needed. For a list of pharmacies that participate in the automatic savings program, patients can visit www.instantsavingsprogram.com.

For patients using pharmacies that do not participate in the automatic savings program, the physician should obtain a savings coupon for LINZESS from a sales representative. Patients must present this coupon to their pharmacist along with a prescription for LINZESS. Please remind patients that they may need to show their coupon each time they refill their prescription.

The program will not override step edits or prior authorizations.

Patients on government-funded plans such as Medicare and Medicaid are not eligible for the program and will be excluded at the pharmacy. Click here for Restrictions, Program Rules and Eligibility Requirements.

The program only applies to commercially insured patients with a covered claim.

CASH-PAYING PATIENTS

Cash-paying patients need a coupon to receive savings on their prescription for LINZESS. Physicians should obtain the coupon for LINZESS from a sales representative and give it to their cash-paying patients.

Forest Laboratories, Inc. and Ironwood Pharmaceuticals, Inc. reserve the right to change or end this program at any time without notice.



LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC).

Important Safety Information

WARNING: PEDIATRIC RISK
LINZESS is contraindicated in pediatric patients under 6 years of age. In nonclinical studies, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration in young juvenile mice. Use of LINZESS should be avoided in pediatric patients 6 through 17 years of age. The safety and efficacy of LINZESS has not been established in pediatric patients under 18 years of age.

Contraindications

  • LINZESS is contraindicated in pediatric patients under 6 years of age.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

Pediatric Risk

  • LINZESS is contraindicated in pediatric patients under 6 years of age. The safety and effectiveness of LINZESS in pediatric patients under 18 years of age have not been established. In neonatal mice, increased fluid secretion as a consequence of GC-C agonism resulted in mortality within the first 24 hours due to dehydration. Due to increased intestinal expression of GC-C, children under 6 years of age may be more likely than older children and adults to develop significant diarrhea and its potentially serious consequences.
  • Use of LINZESS should be avoided in pediatric patients 6 through 17 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 through 17 years of age.

Diarrhea

  • Diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS‑C and CIC double-blind placebo-controlled trials. Severe diarrhea was reported in 2% of LINZESS-treated patients. The incidence of diarrhea was similar in the IBS‑C and CIC populations.
  • Patients should be instructed to stop LINZESS if severe diarrhea occurs and to contact their healthcare provider. The healthcare provider should consider dose suspension and rehydration.

Adverse Reactions

  • In IBS‑C clinical trials, the most common adverse reactions in LINZESS-treated patients (incidence ≥2% and greater than placebo) were diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
  • In CIC clinical trials, the most common adverse reactions in LINZESS-treated patients (incidence ≥2% and greater than placebo) were diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%).
Please also see the full Prescribing Information for LINZESS.